Evidence map›Paper›PMID 40824382›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Formulation, characterization, and evaluation of transdermal patches of ranolazine for chronic angina pectoris.

Zubair Momin, Manjula D, Premakumari K B, Vijaya Bhaskar K, Lalit Kumar

Abstract read
PubMed Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zubair MominDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, Karnataka, India.
Manjula DDepartment of Pharmaceutics, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, Karnataka, India. manjula-sps@dsu.edu.in.
Premakumari K BDepartment of Pharmaceutical Chemistry, College of Pharmaceutical Sciences, Dayananda Sagar University, Bengaluru, Karnataka, India.
Vijaya Bhaskar KDepartment of Pharmaceutical Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, 576 104, Karnataka, India.
Lalit KumarDepartment of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hajipur, 844 102, Vaishali, Bihar, India. lalit.kumar@niperhajipur.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T his study is aimed at developing and evaluating matrix-type transdermal patches of ranolazine (Rn) to enhance its bioavailability and therapeutic efficacy in chronic angina pectoris. Patches were formulated using the mercury substrate method with polymers such as ethyl cellulose, HPMC, PMMA, and sodium alginate. Among the twelve formulations, F6 was optimized based on physical and other performance parameters. The F6 patches showed a drug content of 96.44 ± 0.15%, thickness of 0.227 ± 0.11 mm, weight of 106.90 ± 0.03 mg, and folding endurance of 94 ± 0.19. Moisture loss and water vapor transmission rate were found to be 4.92 ± 0.03% and 0.00043 ± 0.05 g/cm

Indexed as

Angina PectorisCardiovascular AgentsRanolazineTransdermal PatchAdministration, CutaneousAnimalsBiological AvailabilityChemistry, PharmaceuticalChronic DiseaseDrug LiberationDrug StabilityMaleRatsRats, Sprague-DawleySkinSkin AbsorptionCardiovascular AgentsRanolazineAngina pectorisBioavailabilityRanolazineTransdermal patches

Identifiers

PMID40824382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.